Hikal Limited Reports Audited Standalone and Consolidated Financial Results for the Year Ended March 31, 2017
August 23, 2017 at 01:44 am EDT
Share
Hikal Limited reported audited standalone and consolidated financial results for the year ended March 31, 2017. For the year, on standalone basis, the company reported revenue from operations of INR 10,139.36 million against INR 9,256.49 million a year ago. Total revenue was INR 10,173.71 million against INR 9,274.90 million a year ago. Profit before tax was INR 829.39 million against INR 533.06 million a year ago. Profit for the year was INR 667.94 million or INR 8.13 per basic and diluted share against INR 413.17 million or INR 5.03 per basic and diluted share a year ago. Net cash flow generated from operating activities was INR 1,634.91 million against INR 1,857.00 million a year ago. Purchase of property, plant and equipment was INR 1,221.05 million against INR 588.36 million a year ago.
For the year, on consolidated basis, the company reported revenue from operations of INR 10,139.36 million against INR 9,256.49 million a year ago. Total revenue was INR 10,173.71 million against INR 9,274.90 million a year ago. Profit before exceptional item and tax was INR 842.38 million against INR 531.90 million a year ago. Profit before tax was INR 800.24 million against INR 531.90 million a year ago. Profit for the year was INR 638.79 million or INR 7.77 per basic and diluted share against INR 412.01 million or INR 5.01 per basic and diluted share a year ago. Net cash flow generated from operating activities was INR 1,634.99 million against INR 1,856.07 million a year ago. Purchase of property, plant and equipment was INR 1,221.05 million against INR 588.36 million a year ago.
Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. Its human health product categories include anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-viral, anti-inflammatory, analgesic and anti-parasitic. Its animal health product categories include anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone and NSAID. Its crop protection product categories include algaecide, biocide, fungicide, herbicide, insecticide and intermediate.
HIKAL LIMITED 
